|
USA-1255-All कंपनी निर्देशिकाएँ
|
कंपनी समाचार :
- Ph I II Study of NVL-655 Patients with Advanced NSCLC and . . .
Phase 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation Phase 2; a Cohorts 2a, 2b, and 2c: Histologically or cytologically confirmed locally advanced or metastatic NSCLC with a documented ALK rearrangement b
- UC Irvine Solid Tumor Trial → NVL-655 in Patients With . . .
Cohort 2d: Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, who are naïve to ALK TKI therapy Up to one prior line of chemotherapy and or immunotherapy is allowed Cohort 2e: Patients with locally advanced or metastatic NSCLC harboring an ALK rearrangement, not eligible for other Phase 2 cohorts
- Biomarker-Specific Survival and Cost for Advanced NSCLC
Key Points Question What are the survival and medication cost for advanced non–small cell lung cancer by biomarker status? Findings In this cohort study using data from 26 635 patients, the median overall survival was 39 9 months for ALK rearrangement, 27 0 months for EGFR variation, and 12 to 16 months for 3 programmed cell death 1 ligand 1 (PD-L1) groups
- Final Overall Survival and Long-Term Safety of Lorlatinib in . . .
We present the overall survival (OS) and long-term safety of lorlatinib in patients with advanced ALK-positive NSCLC from the final analyses of the pivotal phase 2 study Methods: Adults with ALK-positive NSCLC, enrolled in expansion cohorts (EXPs) on the basis of prior therapy (EXP1-5), received lorlatinib 100 mg orally once daily in
|
|